PEU	Please type a plus sign (+) inside this box
10 11	in 🔝	the Paperwork Reduction Act
J OCI	Substitute for form 1449/	A/PTO
\a_	SLIDDI EMEN	ΤΔΙ

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

	Complete if Kn wn		
	•	討	
Application Number	09/281,474	至	
Filing Date	March 30, 1999	<u>R</u>	
First Named Inventor	Rajopadhye	z	
Group Art Unit	4 019 1616		- 20
Examiner Name	D. Jones		1
Attorney Docket Number	DM-6958	9	
			_

	U.S. PATENT DOCUMENTS							
U.S. Patent Documer		II S. Botont Degument						
Examiner Initials *	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
			,					
		 						
		 						
		1						
								
		 						
	 	 						
		 						
	ļ	<u> </u>			·			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Fore Office ³	eign Patent Doo Number ⁴	kument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
90)		/wo	99/58162		DuPont Pharmaceuticals	11-18-1999	•	
M	ı	/wo	02/04030		DuPont Pharmaceuticals	01-17-2002		
·								
		-	İ					

$\overline{}$				
Examiner Signature	Dones	Date Considered	1/10/02	1/10/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<u>6=1</u>									
Substitute	for form 1449A/PT()			Compl t if Kn wn	ECH			
SUPPLEMENTAL					. 오				
INICO	DMATION	DIC	CL OCUDE	Application Number	09/281,474	ΞĎ	<u> </u>		
			CLOSURE	Filing Date	March 30, 1999	1	~		
SIAI	EMENTB	ΥA	PPLICANT	First Named Inventor	Rajopadhye	- 33	4		
				Group Art Unit	1819-1616	<u></u>	7		
	(use as many she	ets as	necessary)	Examiner Name	D. Jones	S	7.0		
Sheet	2	of	2	Attorney Docket Number	DM-6958	<u> </u>			

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
M		*Cilengitide//Oncolytic Angiogenesis Inhibitor Integrin Alphavbeta3, Alphabeta5 Antagonist* Drugs of the Future, Barcelona, ES, vol 7, no 25, 2000, pp 674-678, XP008002380				
D		Liu S et al, "90Y and 177LU Labeling of a Dota-Conjugated Vitornectin Receptor Antagonist Useful for Tumor Therapy" Bioconjugate Chemistry, American Chemical Society, Washington, US, vol 4, no 12, July 2001, pp 559-568, XP001066363				
\mathcal{N}		Burke P A et al., *Combined Modality Radioimmunotherapy//Promise and Peril* Cancer, American Cancer Society, Philadelphia, PA, US, vol suppl 4, no 94, 15 Feb 2002, pp 1320-1331, XP008001988				
•						

Examiner Date 1/10/25				
Signature Considered \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	Examiner Signature	1 Danes	Date Considered	1/10/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.